C2402-03A-ML490
Grade
Affinity PurifiedConjugate
MaxLight™490Specificity
Recognizes the human CD47. Species Crossreactivity: porcine, canine, sheep, bovineApplications
FC IHC IP WBEU Commodity Code
30021010Shipping Temp
Blue IceStorage Temp
4°C Do Not FreezeBSA Free
YesPreservative Free
YesNotes
Preservative Free
BSA Free
CD47 (MaxLight 490)
MaxLight™490 is a new Blue-Green photostable dye conjugate comparable to DyLight™488, Alexa Fluor™488 and offers better labeling efficiency, brighter imaging and increased immunodetection. Absorbance (491nm); Emission (515nm); Extinction Coefficient 73,000.
CD47 is a cell surface glycoprotein that is a heavily N-glycosylated 47-52kD molecule. CD47 is expressed on all cells and tissues so far examined, although expression is reduced on erythrocytes of the rare Rh null phenotype.
Applications
Suitable for use in Immunohistochemistry, Western Blot, Immunoprecipitation and Flow Cytometry. Other applications have not been tested.
Recommended Dilutions
Immunohistochemistry: Frozen sections Western Blot: Recognizes CD47 under non-reducing conditions, the CD47 epitope recognized is lost on reduction Optimal dilutions to be determined by researcher.
Recommended Negative Controls
I1904-84Q3: IgG2b Negative Control
Storage and Stability
Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™490 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Note: Applications are based on unconjugated antibody.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
US Biological application reference: Salajegheh, M. et al., (2007) J Neuroimmunol. 187:166-174. 1. Avent, N. et al. (1988) Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific. Biochem J. 251 (2): 499-505. 2. Campbell, I.G. et al. (1992) An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res. 52 (19): 5416-20. 3. Brown, E. et al. (1990) Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol. 111 (6 Pt 1): 2785-94. 4. Lindberg, F.P. et al. (1993) Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol. 123 (2): 485-96. 5. Ide, K. et al. (2007) Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A. 104 (12): 5062-6. 6. Lecchi, C. et al. (2008) Bovine alpha-1 acid glycoprotein can reduce the chemotaxis of bovine monocytes and modulate CD18 expression. Vet Res. 39: 50. 7. Chao, M.P. et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71 (4): 1374-84. 8. Shahein, Y.E. et al. (2002) Molecular cloning and functional characterization of the pig homologue of integrin-associated protein (IAP/CD47). Immunology. 106: 564-76. 9. Brooke, G. et al. (2004) Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J Immunol. 173: 2562-70. 10. Wewer, C. et al. (2011) Transcellular migration of neutrophil granulocytes through the blood-cerebrospinal fluid barrier after infection with Streptococcus suis. J Neuroinflammation. 8: 51. 11. Ticchioni, M. et al. (2001) Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow. FASEB J. 15: 341-50. 12. Chao, M.P. et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. 13. Siddhartha, J et al. (2016) Methods of manipulating phagocytosis mediated by CD47. US patent app 15/054930USBio References
US Biological application reference: Salajegheh, M. et al., (2007) J Neuroimmunol. 187:166-174.